KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Liabilities and Shareholders Equity (2016 - 2026)

Astrazeneca has reported Liabilities and Shareholders Equity over the past 18 years, most recently at $114.0 billion for Q1 2026.

  • For Q1 2026, Liabilities and Shareholders Equity rose 7.31% year-over-year to $114.0 billion; the TTM value through Mar 2026 reached $455.0 billion, up 8.44%, while the annual FY2025 figure was $114.1 billion, 9.65% up from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 was $114.0 billion at Astrazeneca, roughly flat from $114.1 billion in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $114.5 billion in Q3 2025 and troughed at $313.0 million in Q4 2023.
  • A 5-year average of $97.3 billion and a median of $102.3 billion in 2024 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 92672.12% in 2022 and later plummeted 99.68% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $96.5 billion in 2022, then plummeted by 99.68% to $313.0 million in 2023, then surged by 33138.02% to $104.0 billion in 2024, then rose by 9.65% to $114.1 billion in 2025, then decreased by 0.05% to $114.0 billion in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for AZN at $114.0 billion in Q1 2026, $114.1 billion in Q4 2025, and $114.5 billion in Q3 2025.